GlassScriptPhysician profile
Chad M Phillips
NPI 1992190359
$4,556.66
in general payments reported to CMS, 2019-2025
22 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $615 · 2023: $863 · 2024: $1,458 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,055.72 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $697.88 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $668.05 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $293.98 | 2023-2025 | Auvelity |
| Lundbeck LLC | $280.63 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $241.83 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $207.48 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $191.49 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $186.80 | 2021-2024 | Austedo Xr, Austedo |
| Alkermes, INC. | $131.13 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $120.71 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.67 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $84.28 | 2022-2024 | |
| Almatica Pharma LLC | $70.31 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $39.67 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.04 | 2024 | Spravato |
| Neos Therapeutics, LP | $29.62 | 2024 | Adzenys Xr-Odt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.40 | 2025 | |
| Noven Therapeutics, LLC | $24.18 | 2024 | Secuado, Xelstrym |
| Tris Pharma INC | $23.21 | 2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $22.06 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.